BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
Davide Simeone, Anna Maria Spera, G. Tosone, R. Orlando. May direct-acting antiviral regimens for chronic hepatitis C virus infections have neuropsychiatric adverse drug reactions? A pilot study conducted in patients receiving sofosbuvir-based regimens in the real-life settingDrugs & Therapy Perspectives 2017; 33(9): 442 doi: 10.1007/s40267-017-0422-x
2
Ruben C. Hoogeveen, Max P.A.M. Sonnen, Sanjay U.C. Sankatsing. Visual Hallucinations During Hepatitis C Treatment With Sofosbuvir and SimeprevirInfectious Diseases in Clinical Practice 2016; 24(6): e65 doi: 10.1097/IPC.0000000000000425
3
Marta Miarons, Azhara Sánchez-Ulayar, Glòria Sempere, Sergio Marín, Josep Maria Castellví. New direct-acting antivirals for hepatitis C treatment and neuropsychiatric symptoms in psychiatric risk groupsEuropean Journal of Hospital Pharmacy 2019; 26(3): 135 doi: 10.1136/ejhpharm-2017-001352
4
Anna Linda Zignego, Manuel Ramos-Casals, Clodoveo Ferri, David Saadoun, Luca Arcaini, Dario Roccatello, Alessandro Antonelli, Anne Claire Desbois, Cloe Comarmond, Laura Gragnani, Milvia Casato, Peter Lamprecht, Alessandra Mangia, Athanasios G Tzioufas, Zobair M Younossi, Patrice Cacoub. International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statementAutoimmunity Reviews 2017; 16(5): 523 doi: 10.1016/j.autrev.2017.03.004
5
Bryan Sackey, Jana G. Shults, Troy A. Moore, Rachel Rogers, Mina Mehvar, Joshua G. King. Evaluating psychiatric outcomes associated with direct-acting antiviral treatment in veterans with hepatitis C infectionMental Health Clinician 2018; 8(3): 116 doi: 10.9740/mhc.2018.05.116